Sponsors and CROs agree that integrating statistical modeling and knowledge of past performance into feasibility analyses improves accuracy of results
![](/46/pdcnewsitem/04/25/36/isr.png)
Informing the pharmaceutical drug development, manufacturing and commercialization industry.
A new report, Best Practices in Study Feasibility, from Industry Standard Research (ISR) reveals insights into how to successfully navigate many of the challenges - medical, clinical, logistical and regulatory - associated with establishing the feasibility of a clinical trial. A key area of interest for readers of the report will be the "Top Techniques and Innovations" for conducting feasibility analyses, where both sponsors and CROs report that the integration of statistical modeling and past performance into feasibility analyses is the number one technique positively affeccting the industry right now.
"ISR surveyed stakeholders from sponsors, CROs and sites to gain insight into feasibility analyses, and with the degree of differences between these groups on objectives and approaches for conducting a feasibility analysis, it is somewhat surprising to see the same concept mentioned as a top technique or innovation from both sponsors and CROs," explained Kate Hammeke, Vice President of Market Research at ISR.
In addition to findings on the top techniques and innovations used when conducting a feasibility analysis, respondents also shared their awareness of feasibility analysis service providers and frequency of use, the percentage of trials that require a feasibility analysis, whether the analysis is conducted in-house or outsourced, the data sources utilized and a ranking of which data sources contribute to the accuracy of the estimate. The report includes key statistics on the characteristics that comprise a predictive feasibility estimate, impressions on the industry's approach to feasibility analysis and the use of SOPs (standard operating procedures) and the accuracy of the estimations received from CROs, sites and specialized feasibility analysis firms as well as the potential value to be gained by engaging a specialized feasibility analysis firm under specific circumstances.
Both sponsors and CROs shared feedback on their experiences working with 23 different specialized feasibility analysis firms,
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance